
Louise S. Clemmensen

# Bringing ideas to life and research to market

BioInnovation Institute



BioInnovation Institute

### **Bringing science to market**

World-class life science research

VC funds Life Science industry Seed funding, sub-licensing or acquisition

#### The situation

- The Nordic is home to world-class life science research
- Increasing number of patent applications

#### However

- Denmark has limited success in translating life-science research into new products and solutions
- In the ecosystem, there is very limited support dedicated to the early stages of life-science start-up development



В

## **Bringing science to market**




#### BII is a Novo Nordisk Foundation initiative:

- Established in January 2018
- Granted DKK 392 million for a 3-years establishment period
- Our main focus is pharma (therapeutics), medtech and industrial biotech
- BII does not work for profit

### Life science entrepreneur?

3

### **BII has everything** you need



## **BII Labs**

375 m<sup>2</sup> open GMO 1 classified general lab

**150 m<sup>2</sup>** open GMO 1 classified **special** labs

- DNA/RNA lab
- Microscope lab
- Cell labs
- One GMO 2 lab

60 m<sup>2</sup> open workshop





## **BII Open Call Programs 2020**



#### **Proof of Concept**



Establish technical feasibility



Grants of up to 1M DKK (up to 10 grants per call)







Located at host research institution



Deadline: 12. March 2020 Last call at BII



#### **Business Acceleration** Academy

Validate commercial potential


Grants of up to 350K DKK (up to 8 grants per call)





New program under development – opens in fall





Grants (academic) or loans (startups) of up to 3.5M DKK



institution or BII



Researchers at Nordic universities/hospitals or startups CVR registered in DK

Located at host research








Deadline: 4. June 2020 Call opens 16. March



#### **Creation House**



Convertible loan of up to 10M DKK (2-4 per call)



(\$

Life science spin-Life science spin-outs CVR



Located at BII



Call opens in spring Deadline: Mid august (TBD)

Maturity of translational project





**Goal:** Stimulate innovation within academia by allowing researchers to establish technical feasibility

#### Who is it for?

- Researchers at Danish universities and/or hospitals with a very early pharma (therapeutics), medtech and bioindustrial project that are **ready to establish the preliminary proof of concept**
- The project must have a clear commercial potential
- Applicants have to be located in Denmark and continue the research at their host institution in Denmark within the duration of 1 year

#### How is it funded?

- A grant for up to DKK 1M
- The grant will be awarded to the host institution
- BII takes no equity



Call opens 16. March Deadline: 4. June

### Preseed



**Goal:** To accelerate the maturity of the life science project by addressing early stage technical and commercial risks in order to attract further funding

**Who is it for?** Early innovation projects that have already shown some proof of concept

#### **Startups**

- CVR registered in Denmark
- Primary team members must have the right to reside and work in Denmark at the time of project initiation
- Owns or has full access to the IPR of their discovery under market terms for early-stage startups

#### How is it funded?

• A founder-friendly convertible loan of up to DKK 3.5 million

#### **Research institutions**

- Researchers at Nordic universities and/or hospitals
- Must present a plan for IPR in the event of commercial spinout
- If any co-applicants from multiple institutions, an IP management agreement must be in place
- A grant of up to DKK 3.5 million
- The grant will be awarded to host institution



### **Creation House**

Goal: To mature and de-risk the company to attract substantial funding

#### Who is it for?

- Companies in pharma (therapeutics), medtech and bioindustrials that have *a solid, initial business plan* and the entrepreneurial skills to execute on it
- CVR registered in Denmark
- Accepted companies must relocate to BII's facilities in Copenhagen
- Control of the IP is a requirement, e.g. through ownership or license agreements

#### How is it funded?

• Through a founder-friendly convertible loan of up to DKK 10 million paid in tranches over an 18 month period



### **Current Company Portfolio in Creation House**



DTU/KU spinout developing a drug candidate that can eradicate CMV to improve transplantation outcome https://synklino.com/



Medtech startup providing easy ondemand, non-hormonal birth control for women

http://getcircle.co/



Biotech startup developing a first-inclass, best-in-class, dual-incretin agonist to slow the progression of Parkinson's disease

https://www.kariyapharma.com



KU spinout (DanStem) developing next generation allogeneic stem cell therapy for type 1 diabetes

http://pancryos.com/



KU spinout developing the world's first adaptive immunooncology therapy targeting immunosuppressive genes of ancient retroviruses that are activated in cancer

http://inprother.com/



AU spinout developing first-in-class sensitizers of the STING pathway as novel immunooncology treatment <u>http://stipetherapeutics.com/</u>

#### 20M EUR Series A in 2019

### **ADCende**

Rigshospitalet/KU spinout developing first-in-class anti-cancer drug, in the form of an antibody-drug conjugate, for soft-tissue sarcoma <u>http://adcendo.dk/</u>



KU spinout developing first-in-class compounds that target essential protein-protein interactions required for error-free DNA damage repair

http://ankrin.com/



#### +4 starting this Spring

## Meet the BII BD Team

#### Who?

Giles Dudley, Senior Business Developer

#### When?

16. March (30 min time slots)

#### Where?

Aarhus University Katrinebjergvej 107, 8200 Aarhus N Building 5530, Room 0.2.09 (ground floor)

#### How?

BioInnovation Institute

Sign up by sending e-mail to: Morten Holmager holmager@au.dk



## Questions?



www.bioinnovationinstitute.com

Email: lcl@novo.dk

B